Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Mantle Cell Lymphoma Mantle Cell Lymphoma for March/April 2020 Angiogenesis, SOX11 expression in MCL positively correlate to increased inflammatory infiltrate, Benefit of allo SCT for MCL offset by increased risk of mortality, GVHD, RB/RC induction followed by ASCT achieved high rates of durable MCL remissions, Case report shows MCL presenting as cryoglobulinemic vasculitis, Trial therapy demonstrates clinical benefit, manageable safety in patients with R/R MCL, More must reads Mantle Cell Lymphoma for January/February 2020 Rare case of nasal cavity mantle cell lymphoma reported, Viral encephalitis associated with 2 cases of rituximab maintenance therapy, Novel BTK inhibitor shows in vitro promise for treating mantle cell lymphoma, Rituximab maintenance after R-CHOP improved PFS/OS in older patients with MCL, Mixed results from replacing carmustine with bendamustine in BEAM therapy for MCL, More must readsMantle Cell Lymphoma for November/December 2019 LOXO-305: Next-Gen BTK Inhibitor Safe and Effective in B-Cell Malignancies, Some MCL Patients Can Safely Stop Venetoclax-Ibrutinib, Study Suggests, KTE-X19 Produces Highest Response Rate in MCL Subgroup, Orelabrutinib Could be ‘Preferred’ BTK Inhibitor for MCL, SOX11 Shows Value as Diagnostic Marker in MCL, More must readsMantle Cell Lymphoma for September/October 2019 Follow-Up Shows Favorable Results With Acalabrutinib in MCL, Staging PET/CT Better Defines Extent of Mantle Cell Lymphoma, Rituximab, Bendamustine Look Better Than Chemo Alone in MCL, More must readsMantle Cell Lymphoma for July/August 2019 Ibrutinib-Rituximab Induction Yields ‘Unprecedented’ Responses in MCL, Ibrutinib/Rituximab Effective, Safe as Frontline Treatment for Older Patients With MCL, Low-Dose Radiation Therapy Looks Effective in Hard-to-Treat MCL, Flavopiridol Elicits Poor Response in Mantle Cell Lymphoma, DLBCL, More must readsPages1 2 3 4 next › last »
